Lymphotropic hepatitis C virus has an interferon-resistant phenotype

Journal of Viral Hepatitis

Volumn 19, Issue 4, 2012, Pages 254-262

  Inokuchi, M ^a   Ito, T ^a   Nozawa, H ^a   Miyashita, M ^a   Morikawa, K ^a   Uchikoshi, M ^a   Shimozuma, Y ^a   Arai, J ^a   Shimazaki, T ^a   Hiroishi, K ^a   Imawari, M ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

B cell disorders; B cell tropism; hepatitis C virus; interferon resistance; lymphoproliferative disorders

Indexed keywords

INTERFERON; INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LYMPHOTROPIC HEPATITIS C VIRUS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; B-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HUMANS; INTERFERONS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL TROPISM;

EID: 84858299112     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01541.x     Document Type: Article

References (31)

1. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-938. (Pubitemid 28275969)
2. Tong MJ, el-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
3. Agnello V, Chung RT, Kaplan LM,. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-1495.
4. Donada C, Crucitti A, Donadon V, et al. Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia. J Viral Hepat 1998; 5: 179-185. (Pubitemid 28374727)
5. Frangeul L, Musset L, Cresta P, et al. Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia. J Hepatol 1996; 25: 427-432. (Pubitemid 26345885)
6. Ferri C, Caracciolo F, Zignego AL, et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol 1994; 88: 392-394. (Pubitemid 24318191)
7. Inokuchi M, Ito T, Uchikoshi M, et al. Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C. J Med Virol 2009; 81: 619-627.
8. Lerat H, Rumin S, Habersetzer F, et al. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood 1998; 91: 3841-3849. (Pubitemid 28225753)
9. Moldvay J, Deny P, Pol S, et al. Detection of hepatitis C virus RNA in peripheral blood mononuclear cells of infected patients by in situ hybridization. Blood 1994; 83: 269-273. (Pubitemid 24016541)
10. Zignego AL, Brechot C,. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol 1999; 31: 369-376. (Pubitemid 29349768)
11. Ito M, Masumi A, Mochida K, et al. Peripheral B cells may serve as a reservoir for persistent hepatitis C virus infection. J Innate Immun 2010; 2: 607-617.
12. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347: 975-982.
13. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)
14. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-230.
15. Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-380. (Pubitemid 41003622)
16. Asselah T, Rubbia-Brandt L, Marcellin P, et al. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55: 123-130. (Pubitemid 41820647)
17. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
18. Laskus T, Radkowski M, Piasek A, et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000; 181: 442-448. (Pubitemid 30131808)
19. Pham TN, MacParland SA, Mulrooney PM, et al. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004; 78: 5867-5874. (Pubitemid 38661674)
20. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41: 106-114. (Pubitemid 40066388)
21. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520. (Pubitemid 24166476)
22. Ito T, Yasui K, Mukaigawa J, et al. Acquisition of susceptibility to hepatitis C virus replication in HepG2 cells by fusion with primary human hepatocytes: establishment of a quantitative assay for hepatitis C virus infectivity in a cell culture system. Hepatology 2001; 34: 566-572. (Pubitemid 32786648)
23. Sung VM, Shimodaira S, Doughty AL, et al. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol 2003; 77: 2134-2146. (Pubitemid 36110026)
24. Rosa D, Saletti G, De Gregorio E, et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 2005; 102: 18544-18549. (Pubitemid 43011262)
25. Stamataki Z, Shannon-Lowe C, Shaw J, et al. Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood 2009; 113: 585-593.
26. Mizuochi T, Ito M, Saito K, et al. Possible recruitment of peripheral blood CXCR3+ CD27+ CD19+ B cells to the liver of chronic hepatitis C patients. J Interferon Cytokine Res 2010; 30: 243-252.
27. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
28. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
29. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-429.
30. Kurosaki M, Tanaka Y, Nishida N, et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011; 54: 439-448.
31. Gale MJ Jr, Korth MJ, Katze MG,. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diagn Virol 1998; 10: 157-162. (Pubitemid 28399034)